Cargando…

It Depends on What Mean Means: Averaging Versus Event Patterning in Analyses of Administrative Claims Data

Detalles Bibliográficos
Autores principales:	Fairman, Kathleen A., Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2010
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437426/ https://www.ncbi.nlm.nih.gov/pubmed/20433219 http://dx.doi.org/10.18553/jmcp.2010.16.4.288

Ejemplares similares

ADD or ADHD or What Exactly?--GIGO Part II and Other Lessons in Research with Administrative Claims
por: Curtiss, Frederic R., et al.
Publicado: (2007)

What Should Be Done About Bias and Misconduct in Clinical Trials?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Protecting Patients from Adverse Drug Events: Propoxyphene, PIMs, and Drugs to Avoid in Older Adults
por: Curtiss, Frederic R., et al.
Publicado: (2011)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008)

What Does It Mean?
Publicado: (1901)

‘Global health’: meaning what?
por: Taylor, Sebastian
Publicado: (2018)

What Does Physiological Mean?
por: Petersen, Ole H
Publicado: (2023)

Still Looking for Health Outcomes in All the Wrong Places? Misinterpreted Observational Evidence, Medication Adherence Promotion, and Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Call for Letters Regarding Disclosure of Potential Conflicts of Interest in the Managed Care Literature -- Too Much, Too Little, or Just About Right?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Clinical Quality Indicators and Provider Financial Incentives: Does Money Matter?
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Does Medicalization of Life Imperil Health? Expanding Indications for Diagnosis and Treatment of Chronic “Disease”
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Managed Care and Health Care Reform: Everything Old Is New Again
por: Fairman, Kathleen A., et al.
Publicado: (2009)

VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Rethinking the Whodunnit Approach to Assessing the Quality of Health Care Research -- A Call to Focus on the Evidence in Evidence-Based Practice
por: Fairman, Kathleen A., et al.
Publicado: (2008)

The Elephant in the Pharmacy: Patient Choice Is the Big Challenge That No One Talks About in Affordability of Prescription Drugs
por: Fairman, Kathleen A., et al.
Publicado: (2007)

Making the World Safe for Evidence-Based Policy: Let's Slay the Biases in Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Lessons Learned from Randomized Trials and Recent Experience with Health Information Technology: Promising Interventions Meet Real-World Patient Care
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Selling Real-World Health Care Research to Reluctant Buyers-Evidence-Based Education or Marketing a Defective Product?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

It's Only a Pharmacoeconomic Model--Believe It or Not
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Evidence-Based Medicing: Beware of Results From Randomized Controlled Trials and Research With Administrative Claims Data
por: Curtiss, Frederic R.
Publicado: (2005)

Brexit and What It Means for Global Health
por: Greenwood, Brian
Publicado: (2018)

What Does AI Mean to You?
por: Sorrell, Vincent L.
Publicado: (2022)

What Is the Price Benchmark to Replace Average Wholesale Price (AWP)?
por: Curtiss, Frederic R.
Publicado: (2010)

New Generation IVF – What does it mean?
por: Ombelet, Wim
Publicado: (2015)

What is the meaning of age‐related change in CFAE?
por: Kumagai, Koichiro
Publicado: (2019)

Indian suicide data: What do they mean?
por: Snowdon, John
Publicado: (2019)

What the Aftermath of the Global Pandemic Will Mean for Neurologists
por: Rutovic, Stela, et al.
Publicado: (2021)

Nonadherence, Clinical Inertia, or Therapeutic Inertia?
por: Allen, J. Daniel, et al.
Publicado: (2009)

Prior Authorization and Clopidogrel Use - The Truth Lies in the Details
por: Jackson, Mark A., et al.
Publicado: (2009)

What do you mean “functional” in ecology? Patterns versus processes
por: Volaire, Florence, et al.
Publicado: (2020)

What is the meaning of becoming PubMed Central journal?
por: Huh, Sun
Publicado: (2016)

What the InBev merger means for health in Africa
por: Hanefeld, Johanna, et al.
Publicado: (2016)

What Does AI Mean to You? – Part 2
por: Sorrell, Vincent L.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4oc32qf3m42enje4uj9lhqtiuf